# Empowering Advanced Alzheimers Disease and Dementia Research Through Remote Patient Monitoring and Cloud-Connected Wearable Devices

> **NIH NIH R44** · AMISSA, INC. · 2024 · $1,419,714

## Abstract

Project Summary
Last year, the care and treatment of roughly 6 million people diagnosed with Alzheimer's disease and related
dementias cost the U.S. approximately $593 billion dollars. The tremendous costs associated with Alzheimer's
disease include direct medical costs, such as doctor visits, hospital stays, and prescription drugs, as well as
indirect costs such as lost wages and productivity for both the affected individuals and their caregivers. According
to the Alzheimer's Association, the total cost of care for the estimated 13 million individuals with Alzheimer's and
other dementias in the United States by 2050 is projected to reach $1.1 trillion. Emerging lifestyle intervention
research is testing whether changes in physical exercise, sleep, socialization, and sedentary behaviors have an
impact on disease onset and progression of symptoms throughout the lifespan. Unfortunately, obtaining real-
world patient-generated health and behavior information to support this research from aging populations is
challenging and often relies on unreliable self-reporting. After years of meetings with 70+ investigators and
scientists at the NIH, the National Alzheimer's Coordinating Center, Alzheimer's Disease Research Centers,
numerous universities, and the Alzheimer's Association we determined and agreed that a consolidated database
of real-life, digital health information does not exist for Alzheimer's and dementia research. During Amissa's
SBIR Phase I, we created software to measure and collect physiological health data passively and unobtrusively
from non-stigmatizing smartwatches including the Apple Watch and Samsung Galaxy watch. This SBIR Phase
II project is critical to expanding that R&D and improving remote health measurements, collecting and sharing
rich digital health datasets, and identifying potential digital biomarkers that correlate to disease detection,
progression, and prevention. Our two software innovations will enable scientific researchers across the world to
utilize consumer-grade smartwatches as passive remote patient monitoring solutions. Researchers, labs,
universities, and healthcare practitioners will be able to create accounts on our platform, enroll her/his volunteer
subjects/patients for a study, and use our free software to collect longitudinal information including health vitals
and behavior data. Specific Aim 1: Develop A Research Platform and Real-World Health Data Marketplace To
Support Academic Research and Enterprise Partnerships. During Phase II R&D, Amissa Health will collaborate
with experts from Wake Forest University, Harvard Medical School, the Massachusetts Alzheimer's Disease
Research Center, Atrium/Advocate Health, Edge Analytics, and Microsoft to develop the first shared research
platform that will apply longitudinal, real-world, wearable sensor measurements to advance research of
dementia-related digital biomarkers and behavioral interventions. Specific Aim 2: Working with Edge Analytics,
a healthcare-focus...

## Key facts

- **NIH application ID:** 10922009
- **Project number:** 2R44AG072981-02A1
- **Recipient organization:** AMISSA, INC.
- **Principal Investigator:** Jon Andrew Corkey
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,419,714
- **Award type:** 2
- **Project period:** 2021-09-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10922009

## Citation

> US National Institutes of Health, RePORTER application 10922009, Empowering Advanced Alzheimers Disease and Dementia Research Through Remote Patient Monitoring and Cloud-Connected Wearable Devices (2R44AG072981-02A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10922009. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*